Skip to main content
Top
Published in: Clinical Orthopaedics and Related Research® 8/2015

01-08-2015 | Symposium: Sex Differences in Musculoskeletal Disease and Science

Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?

Authors: Adele L. Boskey, PhD, Josephine Marino, MPh, Lyudmila Spevak, MS, Nancy Pleshko, PhD, Stephen Doty, PhD, Erin M. Carter, MS, Cathleen L. Raggio, MD

Published in: Clinical Orthopaedics and Related Research® | Issue 8/2015

Login to get access

Abstract

Background

Osteogenesis imperfecta (OI) is a genetic disease characterized by skeletal fragility and deformity. There is extensive debate regarding treatment options in adults with OI. Antiresorptive treatment reduces the number of fractures in growing oim/oim mice, an animal model that reproducibly mimics the moderate-to-severe form of OI in humans. Effects of long-term treatments with antiresorptive agents, considered for treatment of older patients with OI with similar presentation (moderate-to-severe OI) are, to date, unknown.

Questions/purposes

Fourier transform infrared (FTIR) imaging, which produces a map of the spatial variation in chemical composition in thin sections of bone, was used to address the following questions: (1) do oim/oim mice show a sex dependence in compositional properties at 6.5 months of age; (2) is there a sex-dependent response to treatment with antiresorptive agents used in the treatment of OI in humans; and (3) are any compositional parameters in oim/oim mice corrected to wild-type (WT) values after treatment?

Methods

FTIR imaging data were collected from femurs from four to five mice per sex per genotype per treatment. Treatments were 24 weeks of saline, alendronate, or RANK-Fc; and 12 weeks of saline + 12 weeks RANK-Fc and 12 weeks of alendronate + RANK-Fc. FTIR imaging compositional parameters measured in cortical and cancellous bones were mineral-to-matrix ratio, carbonate-to-mineral ratio, crystal size/perfection, acid phosphate substitution, collagen maturity, and their respective distributions (heterogeneities). Because of the small sample size, nonparametric statistics (Mann-Whitney U- and Kruskal-Wallis tests with Bonferroni correction) were used to compare saline-treated male and female mice of different genotypes and treatment effects by sex and genotype, respectively. Statistical significance was defined as p < 0.05.

Results

At 6.5 months, saline-treated male cortical oim/oim bone had increased mineral-to-matrix ratio (p = 0.016), increased acid phosphate substitution (p = 0.032), and decreased carbonate-to-mineral ratio (p = 0.016) relative to WT. Cancellous bone in male oim/oim also had increased mineral-to-matrix ratio (p = 0.016) relative to male WT. Female oim/oim mouse bone composition for all cortical and cancellous bone parameters was comparable to WT (p > 0.05). Only the female WT mice showed a response of mean compositional properties to treatment, increasing mineral-to-matrix after RANK-Fc treatment in cancellous bone (p = 0.036) compared with saline-treated mice. Male oim/oim increased mineral-to-matrix cortical and cancellous bone heterogeneity in response to all long-term treatments except for saline + RANK-Fc (p < 0.04); female oim/oim cortical mineral-to-matrix bone heterogeneity increased with ALN + RANK-Fc and all treatments increased cancellous female oim/oim bone acid phosphate substitution heterogeneity (p < 0.04).

Conclusions

Both oim/oim and WT mice, which demonstrate sex-dependent differences in composition with saline treatment, showed few responses to long-term treatment with antiresorptive agents. Female WT mice appeared to be more responsive; male oim/oim mice showed more changes in compositional heterogeneity. Changes in bone composition caused by these agents may contribute to improved bone quality in oim/oim mice, because the treatments are known to reduce fracture incidence.

Clinical Relevance

The optimal drug therapy for long-term treatment of patients with moderate-to-severe OI is unknown. Based on bone compositional changes in mice, antiresorptive treatments are useful for continued treatment in OI. There is a reported sexual dimorphism in fracture incidence in adults with OI, but to date, no one has reported differences in response to pharmaceutical intervention. This study suggests that such an investigation is warranted.
Literature
1.
go back to reference Bargman R, Huang A, Boskey AL, Raggio C, Pleshko N. RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta. Connect Tissue Res. 2010;51:123–131.PubMedCentralPubMedCrossRef Bargman R, Huang A, Boskey AL, Raggio C, Pleshko N. RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta. Connect Tissue Res. 2010;51:123–131.PubMedCentralPubMedCrossRef
2.
go back to reference Bargman R, Posham R, Boskey A, Carter E, DiCarlo E, Verdelis K, Raggio C, Pleshko N. High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice. Pediatr Res. 2012;72:495–501.PubMedCentralPubMedCrossRef Bargman R, Posham R, Boskey A, Carter E, DiCarlo E, Verdelis K, Raggio C, Pleshko N. High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice. Pediatr Res. 2012;72:495–501.PubMedCentralPubMedCrossRef
3.
go back to reference Bargman R, Posham R, Boskey AL, DiCarlo E, Raggio C, Pleshko N. Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. Osteoporos Int. 2012;23:1141–1150.PubMedCentralPubMedCrossRef Bargman R, Posham R, Boskey AL, DiCarlo E, Raggio C, Pleshko N. Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. Osteoporos Int. 2012;23:1141–1150.PubMedCentralPubMedCrossRef
4.
go back to reference Boskey AL. Infrared spectra and imaging. In: DiMasi E, Gower LB, eds. Biomineralization Sourcebook: Characterization of Biominerals and Biomimetic Materials. Boca Raton, FL, USA: Taylor and Frances Inc; 2014:47–58.CrossRef Boskey AL. Infrared spectra and imaging. In: DiMasi E, Gower LB, eds. Biomineralization Sourcebook: Characterization of Biominerals and Biomimetic Materials. Boca Raton, FL, USA: Taylor and Frances Inc; 2014:47–58.CrossRef
5.
go back to reference Boskey AL, Doty SB. Mineralized tissue: histology, biology and biochemistry. In: Shapiro, JR. Byers, PH, Sponseller, PD. Glorieux F, eds. Osteogenesis Imperfecta: A Translational Approach to Brittle Bone Disease. New York, NY, USA: Academic Press; 2013:31–44. Boskey AL, Doty SB. Mineralized tissue: histology, biology and biochemistry. In: Shapiro, JR. Byers, PH, Sponseller, PD. Glorieux F, eds. Osteogenesis Imperfecta: A Translational Approach to Brittle Bone Disease. New York, NY, USA: Academic Press; 2013:31–44.
6.
go back to reference Boskey AL, Spevak L, Weinstein RS. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int. 2009;20:793–800.PubMedCentralPubMedCrossRef Boskey AL, Spevak L, Weinstein RS. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int. 2009;20:793–800.PubMedCentralPubMedCrossRef
8.
go back to reference Camacho NP, Carroll P, Raggio CL. Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice. Calcif Tissue Int. 2003;72:604–609.PubMedCrossRef Camacho NP, Carroll P, Raggio CL. Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice. Calcif Tissue Int. 2003;72:604–609.PubMedCrossRef
9.
go back to reference Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, Toledano TR, Boskey AL. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int. 2001;69:94–101.PubMedCrossRef Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, Toledano TR, Boskey AL. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int. 2001;69:94–101.PubMedCrossRef
10.
go back to reference Chang SW, Shefelbine SJ, Buehler MJ. Structural and mechanical differences between collagen homo- and heterotrimers. Relevance for the molecular origin of brittle bone disease. Biophys J. 2012;102:640–648.PubMedCentralPubMedCrossRef Chang SW, Shefelbine SJ, Buehler MJ. Structural and mechanical differences between collagen homo- and heterotrimers. Relevance for the molecular origin of brittle bone disease. Biophys J. 2012;102:640–648.PubMedCentralPubMedCrossRef
11.
go back to reference Chipman SD, Sweet HO, McBride DJ Jr, Davisson MT, Marks SC Jr, Shuldiner AR, Wenstrup RJ, Rowe DW, Shapiro JR. Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice. a model of human osteogenesis imperfecta. Proc Natl Acad Sci U S A. 1993;90:1701–1705. Chipman SD, Sweet HO, McBride DJ Jr, Davisson MT, Marks SC Jr, Shuldiner AR, Wenstrup RJ, Rowe DW, Shapiro JR. Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice. a model of human osteogenesis imperfecta. Proc Natl Acad Sci U S A. 1993;90:1701–1705.
12.
go back to reference Coleman RM, Aguilera L, Quinones L, Lukashova L, Poirier C, Boskey A. Comparison of bone tissue properties in mouse models with collagenous and non-collagenous genetic mutations using FTIRI. Bone. 2012;51:920–928.PubMedCentralPubMedCrossRef Coleman RM, Aguilera L, Quinones L, Lukashova L, Poirier C, Boskey A. Comparison of bone tissue properties in mouse models with collagenous and non-collagenous genetic mutations using FTIRI. Bone. 2012;51:920–928.PubMedCentralPubMedCrossRef
13.
go back to reference Delos D, Yang X, Ricciardi BF, Myers ER, Bostrom MPG, Pleshko Camacho N. The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta. J Orthop Res. 2008;26:153–164.PubMedCentralPubMedCrossRef Delos D, Yang X, Ricciardi BF, Myers ER, Bostrom MPG, Pleshko Camacho N. The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta. J Orthop Res. 2008;26:153–164.PubMedCentralPubMedCrossRef
14.
go back to reference Donnelly E, Meredith DS, Nguyen JT, Gladnick BP, Rebolledo BJ, Shaffer AD, Lorich DG, Lane JM, Boskey AL. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res. 2012;27:672–678.PubMedCentralPubMedCrossRef Donnelly E, Meredith DS, Nguyen JT, Gladnick BP, Rebolledo BJ, Shaffer AD, Lorich DG, Lane JM, Boskey AL. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res. 2012;27:672–678.PubMedCentralPubMedCrossRef
15.
go back to reference Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2014;7:CD005088. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2014;7:CD005088.
16.
go back to reference Evans KD, Lau ST, Oberbauer AM, Martin RB. Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta. Bone. 2003;32:268–274.PubMedCrossRef Evans KD, Lau ST, Oberbauer AM, Martin RB. Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta. Bone. 2003;32:268–274.PubMedCrossRef
18.
go back to reference Gentry BA, Ferreira JA, McCambridge AJ, Brown M, Phillips CL. Skeletal muscle weakness in osteogenesis imperfecta mice. Matrix Biol. 2010;29:638–644.PubMedCentralPubMedCrossRef Gentry BA, Ferreira JA, McCambridge AJ, Brown M, Phillips CL. Skeletal muscle weakness in osteogenesis imperfecta mice. Matrix Biol. 2010;29:638–644.PubMedCentralPubMedCrossRef
19.
go back to reference Gourion-Arsiquaud S, Allen MR, Burr DB, Vashishth D, Tang SY, Boskey AL. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone. 2010;46:666–672PubMedCentralPubMedCrossRef Gourion-Arsiquaud S, Allen MR, Burr DB, Vashishth D, Tang SY, Boskey AL. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone. 2010;46:666–672PubMedCentralPubMedCrossRef
20.
go back to reference Gourion-Arsiquaud S, Lukashova L, Power J, Loveridge N, Reeve J, Boskey AL. Fourier transform infrared imaging of femoral neck bone: reduced heterogeneity of mineral-to-matrix and carbonate-to-phosphate and more variable crystallinity in treatment-naive fracture cases compared with fracture-free controls. J Bone Miner Res. 2013;28:150–161.PubMedCentralPubMedCrossRef Gourion-Arsiquaud S, Lukashova L, Power J, Loveridge N, Reeve J, Boskey AL. Fourier transform infrared imaging of femoral neck bone: reduced heterogeneity of mineral-to-matrix and carbonate-to-phosphate and more variable crystallinity in treatment-naive fracture cases compared with fracture-free controls. J Bone Miner Res. 2013;28:150–161.PubMedCentralPubMedCrossRef
21.
go back to reference Grabner B, Landis WJ, Roschger P, Rinnerthaler S, Peterlik H, Klaushofer K, Fratzl P. Age- and genotype-dependence of bone material properties in the osteogenesis imperfecta murine model (oim). Bone. 2001;29:453–457.PubMedCrossRef Grabner B, Landis WJ, Roschger P, Rinnerthaler S, Peterlik H, Klaushofer K, Fratzl P. Age- and genotype-dependence of bone material properties in the osteogenesis imperfecta murine model (oim). Bone. 2001;29:453–457.PubMedCrossRef
22.
23.
go back to reference Kuznetsova NV, McBride DJ, Leikin S. Changes in thermal stability and microunfolding pattern of collagen helix resulting from the loss of alpha2(I) chain in osteogenesis imperfecta murine. J Mol Biol. 2003;331:191–200.PubMedCrossRef Kuznetsova NV, McBride DJ, Leikin S. Changes in thermal stability and microunfolding pattern of collagen helix resulting from the loss of alpha2(I) chain in osteogenesis imperfecta murine. J Mol Biol. 2003;331:191–200.PubMedCrossRef
24.
go back to reference Laurent M, Gielen E, Claessens F, Boonen S, Vanderschueren D. Osteoporosis in older men: recent advances in pathophysiology and treatment. Best Pract Res Clin Endocrinol Metab. 2013;27:527–539.PubMedCrossRef Laurent M, Gielen E, Claessens F, Boonen S, Vanderschueren D. Osteoporosis in older men: recent advances in pathophysiology and treatment. Best Pract Res Clin Endocrinol Metab. 2013;27:527–539.PubMedCrossRef
25.
go back to reference Lindahl K, Langdahl B, Ljunggren O, Kindmark A. Therapy of endocrine disease. Treatment of osteogenesis imperfecta in adults. Eur J Endocrinol. 2014;171:R79–R90.PubMedCrossRef Lindahl K, Langdahl B, Ljunggren O, Kindmark A. Therapy of endocrine disease. Treatment of osteogenesis imperfecta in adults. Eur J Endocrinol. 2014;171:R79–R90.PubMedCrossRef
26.
go back to reference Marini JC, Reich A, Smith SM. Osteogenesis imperfect due to mutations in non-collagenous genes. lessons in the biology of bone formation. Curr Opin Pediatr. 2014;26:500–507.PubMedCrossRef Marini JC, Reich A, Smith SM. Osteogenesis imperfect due to mutations in non-collagenous genes. lessons in the biology of bone formation. Curr Opin Pediatr. 2014;26:500–507.PubMedCrossRef
27.
go back to reference McCarthy EA, Raggio CL, Hossack MD, Miller EA, Jain S, Boskey AL, Camacho NP. Alendronate treatment for infants with osteogenesis imperfecta. Demonstration of efficacy in a mouse model. Pediatr Res. 2002;52:660–670.PubMedCrossRef McCarthy EA, Raggio CL, Hossack MD, Miller EA, Jain S, Boskey AL, Camacho NP. Alendronate treatment for infants with osteogenesis imperfecta. Demonstration of efficacy in a mouse model. Pediatr Res. 2002;52:660–670.PubMedCrossRef
28.
go back to reference Miles CA, Sims TJ, Camacho NP, Bailey AJ. The role of the alpha2 chain in the stabilization of the collagen type I heterotrimer. A study of the type I homotrimer in oim mouse tissues. J Mol Biol. 2002;321:797–805.PubMedCrossRef Miles CA, Sims TJ, Camacho NP, Bailey AJ. The role of the alpha2 chain in the stabilization of the collagen type I heterotrimer. A study of the type I homotrimer in oim mouse tissues. J Mol Biol. 2002;321:797–805.PubMedCrossRef
29.
go back to reference Misof BM, Roschger P, Baldini T, Raggio CL, Zraick V, Root L, Boskey AL, Klaushofer K, Fratzl P, Camacho NP. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone. 2005;36:150–158.PubMedCrossRef Misof BM, Roschger P, Baldini T, Raggio CL, Zraick V, Root L, Boskey AL, Klaushofer K, Fratzl P, Camacho NP. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone. 2005;36:150–158.PubMedCrossRef
30.
go back to reference Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, Doro F, Perlini S, Cavarzere P, Antoniazzi F. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010;6:367–381.PubMedCentralPubMed Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, Doro F, Perlini S, Cavarzere P, Antoniazzi F. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010;6:367–381.PubMedCentralPubMed
31.
go back to reference Niyibizi C, Smith P, Mi Z, Phillips CL, Robbins P. Transfer of proalpha2(I) cDNA into cells of a murine model of human osteogenesis imperfecta restores synthesis of type I collagen comprised of alpha1(I) and alpha2(I) heterotrimers in vitro and in vivo. J Cell Biochem. 2001;83:84–91.PubMedCrossRef Niyibizi C, Smith P, Mi Z, Phillips CL, Robbins P. Transfer of proalpha2(I) cDNA into cells of a murine model of human osteogenesis imperfecta restores synthesis of type I collagen comprised of alpha1(I) and alpha2(I) heterotrimers in vitro and in vivo. J Cell Biochem. 2001;83:84–91.PubMedCrossRef
32.
go back to reference Pfeiffer BJ, Franklin CL, Hsieh FH, Bank RA, Phillips CL. Alpha 2(I) collagen deficient oim mice have altered biomechanical integrity, collagen content, and collagen crosslinking of their thoracic aorta. Matrix Biol. 2005;24:451–458.PubMedCrossRef Pfeiffer BJ, Franklin CL, Hsieh FH, Bank RA, Phillips CL. Alpha 2(I) collagen deficient oim mice have altered biomechanical integrity, collagen content, and collagen crosslinking of their thoracic aorta. Matrix Biol. 2005;24:451–458.PubMedCrossRef
33.
go back to reference Rao SH, Evans KD, Oberbauer AM, Martin RB. Bisphosphonate treatment in the oim mouse model alters bone modeling during growth. J Biomech. 2008;41:3371–3376PubMedCentralPubMedCrossRef Rao SH, Evans KD, Oberbauer AM, Martin RB. Bisphosphonate treatment in the oim mouse model alters bone modeling during growth. J Biomech. 2008;41:3371–3376PubMedCentralPubMedCrossRef
34.
go back to reference Shapiro JR, McBride DJ Jr, Fedarko NS. OIM and related animal models of osteogenesis imperfecta. Connect Tissue Res. 1995;31:265–268.PubMedCrossRef Shapiro JR, McBride DJ Jr, Fedarko NS. OIM and related animal models of osteogenesis imperfecta. Connect Tissue Res. 1995;31:265–268.PubMedCrossRef
35.
go back to reference Vannleene M, Porter A, Guillot PV, Boyde A, Oyen M, Shefelbine S. Ultra-structural defects cause low bone matrix stiffness despite high mineralization in osteogenesis imperfecta mice. Bone. 2012;50:1317–1323.CrossRef Vannleene M, Porter A, Guillot PV, Boyde A, Oyen M, Shefelbine S. Ultra-structural defects cause low bone matrix stiffness despite high mineralization in osteogenesis imperfecta mice. Bone. 2012;50:1317–1323.CrossRef
36.
go back to reference Vanleene M, Saldanha Z, Cloyd KL, Jell G, Bou-Gharios G, Bassett JH, Williams GR, Fisk NM, Oyen ML, Stevens MM, Guillot PV, Shefelbine SJ. Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties. Blood. 2011;117:1053–1060.PubMedCrossRef Vanleene M, Saldanha Z, Cloyd KL, Jell G, Bou-Gharios G, Bassett JH, Williams GR, Fisk NM, Oyen ML, Stevens MM, Guillot PV, Shefelbine SJ. Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties. Blood. 2011;117:1053–1060.PubMedCrossRef
37.
go back to reference Vanleene M, Shefelbine SJ. Therapeutic impact of low amplitude high frequency whole body vibrations on the osteogenesis imperfecta mouse bone. Bone. 2013;53:507–514.PubMedCentralPubMedCrossRef Vanleene M, Shefelbine SJ. Therapeutic impact of low amplitude high frequency whole body vibrations on the osteogenesis imperfecta mouse bone. Bone. 2013;53:507–514.PubMedCentralPubMedCrossRef
38.
go back to reference Weis SM, Emery JL, Becker KD, McBride DJ Jr, Omens JH, McCulloch AD. Myocardial mechanics and collagen structure in the osteogenesis imperfecta murine (oim). Circ Res. 2000;87:663–669.PubMedCrossRef Weis SM, Emery JL, Becker KD, McBride DJ Jr, Omens JH, McCulloch AD. Myocardial mechanics and collagen structure in the osteogenesis imperfecta murine (oim). Circ Res. 2000;87:663–669.PubMedCrossRef
39.
go back to reference Wekre LL, Eriksen EF, Falch JA. Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta. Arch Osteoporos. 2011;6:31–38.PubMedCentralPubMedCrossRef Wekre LL, Eriksen EF, Falch JA. Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta. Arch Osteoporos. 2011;6:31–38.PubMedCentralPubMedCrossRef
40.
go back to reference Willinghamm MD, Brodt MD, Lee KL, Stephens AL, Ye J, Silva MJ. Age-related changes in bone structure and strength in female and male BALB/c mice. Calcif Tissue Int. 2010;86:470–483.PubMedCrossRef Willinghamm MD, Brodt MD, Lee KL, Stephens AL, Ye J, Silva MJ. Age-related changes in bone structure and strength in female and male BALB/c mice. Calcif Tissue Int. 2010;86:470–483.PubMedCrossRef
41.
go back to reference Yao X, Carleton SM, Kettle AD, Melander J, Phillips CL, Wang Y. Gender-dependence of bone structure and properties in adult osteogenesis imperfecta murine model. Ann Biomed Eng. 2013;41:1139–1149.PubMedCentralPubMedCrossRef Yao X, Carleton SM, Kettle AD, Melander J, Phillips CL, Wang Y. Gender-dependence of bone structure and properties in adult osteogenesis imperfecta murine model. Ann Biomed Eng. 2013;41:1139–1149.PubMedCentralPubMedCrossRef
Metadata
Title
Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
Authors
Adele L. Boskey, PhD
Josephine Marino, MPh
Lyudmila Spevak, MS
Nancy Pleshko, PhD
Stephen Doty, PhD
Erin M. Carter, MS
Cathleen L. Raggio, MD
Publication date
01-08-2015
Publisher
Springer US
Published in
Clinical Orthopaedics and Related Research® / Issue 8/2015
Print ISSN: 0009-921X
Electronic ISSN: 1528-1132
DOI
https://doi.org/10.1007/s11999-015-4268-z

Other articles of this Issue 8/2015

Clinical Orthopaedics and Related Research® 8/2015 Go to the issue

Symposium: Sex Differences in Musculoskeletal Disease and Science

How Does Bone Strength Compare Across Sex, Site, and Ethnicity?